Global Health Ltd

Crisil Ratings stated that GHL's Revenue reported 12% on-year growth in the first nine months of fiscal 2025, driven by increase in inpatient volumes owing to bed expansion, improvement in average revenue per occupied bed (ARPOB) and sustenance of occupancy levels on year on-year basis. Operating profitability moderated by 50 basis points (bps) to 24.1% in the first nine months of fiscal 2025 due to decline in operating profitability in the Lucknow hospital while the Patna (Bihar) and Gurugram (Haryana) hospitals registered stable profitability. At a consolidated level, GHL's revenue may grow 10-12% in fiscal 2025, supported by bed additions, sustenance of occupancy levels at overall level and improvement in ARPOB due to change in case mix. Operating profitability is expected to sustain at 22-24% despite the moderation expected in the Lucknow hospital due to better profitability in other hospitals, although pre-operative expenses towards bed additions at existing hospitals and commencement of the hospital at Noida (Uttar Pradesh) expected towards the end of fiscal 2025 might partly constrain profitability. On consolidated basis, revenue grew 21% to Rs 3,278 crore in fiscal 2024 (from Rs 2,712 crore in fiscal 2023), driven by higher inpatient volumes, changes in specialty mix towards higher value specialties leading to better ARPOB as well as better scale up of the Lucknow and Patna hospitals. The financial risk profile is supported by strong capital structure, healthy debt protection metrics and liquidity. Consolidated adjusted networth stood at Rs 2,900 crore and debt (including lease liabilities) at Rs 802 crore as on 31 March 2024, with gearing at 0.28 time. GHL has planned capital expenditure (capex) of more than Rs ~2,500 crore over the next 3-5 fiscals. The capex will be funded through a prudent mix of cash accrual and debt. Even though the company may avail of external debt, gearing is expected below 0.5 time over the medium term. The ratings continue to reflect the experienced management of GHL in therapeutic segments and healthy financial risk profile. These strengths are partially offset by risks related to implementation and timely stabilisation of upcoming hospitals, geographic and therapeutic segmental concentration in revenue and exposure to intense competition. Global Health operates hospitals in Gurugram, Indore, Ranchi, Lucknow and Patna. The company's consolidated operational bed count stood at nearly 2,373 beds as on 31 March 2024. The scrip shed 0.64% to currently trade at Rs 1227.95 on the BSE. Powered by Capital Market - Live

Global Health has received affirmation in credit ratings from CRISIL Ratings pursuant to merger of Medanta Holdings (MHPL), erstwhile wholly owned subsidiary with the Company as per below details: Total Bank Loan Facilities Rated - Rs. 1500 crore* (Enhanced from Rs. 950 crore) Long Term Rating - CRISIL AA-/Positive (Reaffirmed) Short-term rating - CRISIL A1+ (Reaffirmed) *Earlier rating of MHPL was for Rs. 550 crore which was added in approved limit of GHL i.e. Rs. 950 crore. Powered by Capital Market - Live

Global Health has received reaffirmation in credit rating for bank facilities of Rs 950 crore at CRISIL AA-; Positive/ CRISIL A1+. Powered by Capital Market - Live

Net profit of Global Health rose 15.59% to Rs 142.91 crore in the quarter ended December 2024 as against Rs 123.64 crore during the previous quarter ended December 2023. Sales rose 12.79% to Rs 943.44 crore in the quarter ended December 2024 as against Rs 836.45 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales943.44836.45 13 OPM %25.2025.82 - PBDT237.51216.35 10 PBT189.07172.37 10 NP142.91123.64 16 Powered by Capital Market - Live

Global Health will hold a meeting of the Board of Directors of the Company on 4 February 2025.Powered by Capital Market - Live

Net profit of Global Health rose 4.54% to Rs 130.84 crore in the quarter ended September 2024 as against Rs 125.16 crore during the previous quarter ended September 2023. Sales rose 13.34% to Rs 956.56 crore in the quarter ended September 2024 as against Rs 843.94 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales956.56843.94 13 OPM %23.8625.22 - PBDT230.53213.51 8 PBT181.10170.60 6 NP130.84125.16 5 Powered by Capital Market - Live

Global Health will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live

Global Health announced that the Company has signed an Operations and Management Agreement with Dr. Narayan Dutt Shirmali Foundation International Charitable Trust Society (Society) to operate and manage a ~750 bed super specialty hospital in Pitampura, New Delhi. The hospital is expected to commence operations in ~4 years, subject to necessary statutory and customary approvals. As per the agreement, the hospital building and associated civil infrastructure will be developed by the Society and Medanta will make the necessary investments in internal fitouts, MEP, furniture and medical equipment. Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years, to be funded by a combination of internal accruals and debt financing. Medanta will have full control over the day to day running of the hospital. The agreement is for an initial term of 30 years, further extendable on mutually agreeable terms. The hospital will be located on a 7-acre site in Pitampura, New Delhi, with a total builtup area of 7.6 Lakh sq.ft excluding the basement. The site offers good connectivity to the Outer Ring road and is in close proximity to high-density residential areas, which will enable Medanta to serve the region's growing healthcare needs. The state-of-the-art ~750 bedded super-specialty hospital will cater to over 30 super specialties including cardiac, neurosciences, cancer, orthopaedics, digestive, hepatobiliary sciences, multispecialty robotic surgeries, regenerative medicine, as well as full range of transplants. Powered by Capital Market - Live

Global Health announced that the 20th Annual General Meeting (AGM) of the company will be held on 19 September 2024.Powered by Capital Market - Live

Net profit of Global Health rose 4.20% to Rs 106.29 crore in the quarter ended June 2024 as against Rs 102.01 crore during the previous quarter ended June 2023. Sales rose 10.45% to Rs 861.08 crore in the quarter ended June 2024 as against Rs 779.58 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales861.08779.58 10 OPM %21.6423.66 - PBDT190.27181.43 5 PBT143.65141.04 2 NP106.29102.01 4 Powered by Capital Market - Live